A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)

被引：3
|
作者：
Jhaveri, K. [1 ]
Chandarlapaty, S. [1 ]
Lake, D. [1 ]
Gilewski, T. [1 ]
Drullinsky, P. [1 ]
Sugarman, S. [1 ]
Wasserheit-Leiblich, C. [1 ]
Moynahan, M. E. [1 ]
D'Andrea, G. [1 ]
Haque, S. [1 ]
Patil, S. [1 ]
Bauman, L. [1 ]
Vukovic, V. [1 ]
El-Hariry, I. [1 ]
Hudis, C. [1 ]
Modi, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-08
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL WITH RFS2000 IN PATIENTS (PTS) WITH ADVANCED AND/OR METASTATIC BREAST CANCER (MBC)
    Sorio, R.
    Chollet, P.
    Caponigro, F.
    Carteni, G.
    Sealone, S.
    Crivellari, D.
    Magri, M. D.
    Adank, S. J.
    Veronesi, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 18 - 18
  • [2] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [3] Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC)
    Traina, T. A.
    Sparano, J. A.
    Caravelli, J.
    Patil, S.
    Abbruzzi, A.
    Hawke, R.
    Bromberg, J.
    Nonemaker, J.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [5] Phase II trial of weekly docetaxel (DOC) and prolonged capecitabine (C) in metastatic breast cancer (MBC) patients (pts).
    Shapiro, CL
    Ramaswamy, B
    Rhoades, C
    Kendra, K
    Allen, J
    Hauger, M
    Loughlin, H
    Moore, T
    Villalona, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S203
  • [6] Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC).
    Mundhenke, Christoph
    Schem, Christian
    Bauerschlag, Dirk Olaf
    Weigel, Marion T.
    Wenners, Antonia Sophie
    Schaefer, Fritz Werner
    Tiemann, Katharina
    Hanson, Sven
    Muth, Mathias
    May, Christoph
    Jonat, Walter
    Maass, Nicolai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, E. P.
    Bagegni, N. A.
    Beck, J. T.
    Cultrera, J. L.
    Dosunmu, O.
    Gwin, W. R.
    Heeke, A. L.
    Khoury, K.
    Sellami, D.
    Shastry, M.
    Sternberg, D. W.
    Toppmeyer, D.
    Wright-Browne, V. M.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S220 - S220
  • [8] Phase II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer (MBC)
    Luu, T.
    Frankel, P.
    Chung, C.
    Mortimer, J.
    Hurria, A.
    Somlo, G.
    CANCER RESEARCH, 2010, 70
  • [9] Final results of a phase II clinical and pharmacokinetical trial with oral idarubicin (IDA) in elderly patients (pts) with metastatic breast cancer (MBC).
    Crivellari, D
    Lombardi, D
    Sorio, R
    La Mura, N
    Massacesi, C
    Lucenti, A
    Ferro, A
    Veronesi, A
    Corona, G
    Toffoli, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S
  • [10] A phase II study of the prateasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
    Brown, J
    Von Roenn, J
    O'Regan, R
    Bergan, R
    Badve, S
    Rademaker, A
    Feehan, S
    Petersen, J
    Patton, M
    Gradishar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 14S - 14S
12345